title: Characteristics and expectations of patients with erectile dysfunction: results of the SCORED study.
abstract: In an observational study in men with erectile dysfunction (ED) consulting a general practitioner (GP) or urologist in Belgium, demographics, ED characteristics (including erection hardness score), co-morbidities and treatment expectations were evaluated using a structured questionnaire. In total, 341 GPs and 41 urologists recruited 1492 patients. Most (74%) were untreated and 25% had ED for >3 years. Considering PDE5 inhibitors, erection hardness (89%) and maintenance (92%) were considered 'very important' by most patients. Only 18% of physicians initiated discussion about ED, despite 41% of patients having >or=3 known risk factors. The questionnaire was considered helpful by 81% of GPs and 83% of their patients. Overall, patients are under-diagnosed, and physicians are reluctant to ask about ED. A questionnaire including erection hardness score is useful to facilitate discussion about ED in general practice. Erection hardness and maintenance are more important to patients as compared to fast onset or long duration of action.
authors.affiliation: Department of Urology, UZ Gasthuisberg, Leuven, Belgium. Hubert.Claes@scarlet.be
authors.forename: H
authors.initials: H
authors.lastname: Claes
authors.forename: R-J
authors.initials: RJ
authors.lastname: Opsomer
authors.forename: R
authors.initials: R
authors.lastname: Andrianne
authors.forename: S
authors.initials: S
authors.lastname: Vanbelle
authors.forename: A
authors.initials: A
authors.lastname: Albert
authors.forename: F
authors.initials: F
authors.lastname: Vanderdonck
mesh_terms: D054706:Cyclic Nucleotide Phosphodiesterases, Type 5 / Q000378:metabolism; D007172:Erectile Dysfunction / Q000188:drug therapy / Q000201:enzymology / Q000503:physiopathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D012307:Risk Factors; D011795:Surveys and Questionnaires
chemical_list: D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5